The earnings call highlighted strong financial performance and strategic advancements, including innovation and successful M&A integration. However, challenges in key segments such as pharma and biotech, as well as flat growth in diagnostics and healthcare, present headwinds. The company's proactive measures and raised guidance indicate optimism, but the balanced nature of highlights and lowlights suggests cautious optimism.

Company Guidance

During the Thermo Fisher Scientific Q3 2024 earnings call, the company provided guidance reflecting strong financial performance and strategic positioning. They reported revenue of $10.6 billion, adjusted operating income of $2.36 billion, and an adjusted operating margin of 22.3%. The adjusted EPS was $5.28, prompting an upward revision of their full-year adjusted EPS guidance to a range of $21.35 to $22.07, while maintaining revenue expectations between $42.4 billion and $43.3 billion. The company noted sequential improvements in organic revenue growth, which was flat year-over-year but offset by a 3% headwind from declining pandemic-related revenues. They highlighted robust performance in their electron microscopy and clinical research businesses, despite a low single-digit decline in the pharma and biotech sector due to vaccine and therapy runoff. Looking ahead, Thermo Fisher anticipates continued organic growth and strategic investments, leveraging their PPI Business System and capital deployment strategy to drive future success.

Strong Financial Performance

Thermo Fisher Scientific reported Q3 revenue of $10.6 billion and adjusted operating income of $2.36 billion, with an adjusted operating margin of 22.3% and adjusted EPS of $5.28.

Adjusted EPS Guidance Raised

The company raised its adjusted EPS guidance to a range of $21.35 to $22.07 for 2024, reflecting strong performance and financial management.

Innovation and Product Launches

The company received industry recognition for its innovative products, including the Gibco CTS Detachable Dynabeads and Thermo Scientific Orbitrap Astral Mass Spectrometer, and launched the Thermo Scientific Iliad scanning transmission electron microscope.

Strong Growth in Analytical Instruments

The Analytical Instruments segment showed 3% organic growth, driven by strong demand in electron microscopy and new product launches.

Successful M&A Integration

The integration of OLink and the performance of The Binding Site were highlighted as successful, contributing to the company's growth strategy.

Customer Wins and Strategic Partnerships

Thermo Fisher announced a partnership with the National Cancer Institute and highlighted significant commercial wins, enhancing its trusted partner status.

---

Thermo Fisher (TMO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TMO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jul 25, 2018	2018 (Q2)	- / 2.75	2.3	19.57% (+0.45)	―	―
Oct 24, 2018	2018 (Q3)	- / 2.62	2.31	13.42% (+0.31)	―	―
Jan 30, 2019	2018 (Q4)	- / 3.25	2.79	16.49% (+0.46)	―	―
Apr 24, 2019	2019 (Q1)	- / 2.81	2.5	12.40% (+0.31)	―	―
Jul 24, 2019	2019 (Q2)	- / 3.04	2.75	10.55% (+0.29)	―	―
Oct 23, 2019	2019 (Q3)	- / 2.94	2.62	12.21% (+0.32)	―	―
Jan 30, 2020	2019 (Q4)	- / 3.55	3.25	9.23% (+0.30)	―	―
Apr 22, 2020	2020 (Q1)	- / 2.94	2.81	4.63% (+0.13)	―	―
Jul 22, 2020	2020 (Q2)	- / 3.89	3.04	27.96% (+0.85)	―	―
Oct 21, 2020	2020 (Q3)	- / 5.63	2.94	91.50% (+2.69)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

TMO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 23, 2024	$585.94	$576.06	-1.69%
Jul 24, 2024	$551.48	$573.94	+4.07%
Apr 24, 2024	$573.41	$576.20	+0.49%
Jan 31, 2024	$565.58	$537.52	-4.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---